Garry V. Krepart

1.5k total citations
30 papers, 1.1k citations indexed

About

Garry V. Krepart is a scholar working on Reproductive Medicine, Obstetrics and Gynecology and Surgery. According to data from OpenAlex, Garry V. Krepart has authored 30 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Reproductive Medicine, 12 papers in Obstetrics and Gynecology and 6 papers in Surgery. Recurrent topics in Garry V. Krepart's work include Ovarian cancer diagnosis and treatment (20 papers), Endometrial and Cervical Cancer Treatments (11 papers) and Lymphoma Diagnosis and Treatment (5 papers). Garry V. Krepart is often cited by papers focused on Ovarian cancer diagnosis and treatment (20 papers), Endometrial and Cervical Cancer Treatments (11 papers) and Lymphoma Diagnosis and Treatment (5 papers). Garry V. Krepart collaborates with scholars based in Canada and United States. Garry V. Krepart's co-authors include Robert Lotocki, M. Heywood, J.F. Jeffrey, Jill Nation, Tung B. K. Le, Felix N. Rutledge, Julian P. Smith, Tien Le, Michael Helewa and Luis Delclos and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and American Journal of Obstetrics and Gynecology.

In The Last Decade

Garry V. Krepart

30 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Garry V. Krepart Canada 19 798 518 421 170 127 30 1.1k
Ernst Simonsen Sweden 14 499 0.6× 457 0.9× 271 0.6× 108 0.6× 73 0.6× 24 791
A.C.M. van Lindert Netherlands 11 401 0.5× 265 0.5× 370 0.9× 186 1.1× 130 1.0× 17 768
G Bratina Italy 14 750 0.9× 414 0.8× 288 0.7× 113 0.7× 65 0.5× 24 1.1k
Jackson B. Beecham United States 18 760 1.0× 723 1.4× 330 0.8× 248 1.5× 102 0.8× 38 1.3k
R E Scully United States 13 597 0.7× 320 0.6× 251 0.6× 142 0.8× 68 0.5× 13 916
Jan C. Seski United States 17 392 0.5× 745 1.4× 466 1.1× 161 0.9× 75 0.6× 28 1.1k
Charles Whitney United States 10 483 0.6× 354 0.7× 199 0.5× 119 0.7× 164 1.3× 12 743
Larry E. Puls United States 14 588 0.7× 301 0.6× 237 0.6× 130 0.8× 91 0.7× 29 868
Mario Valenzano Menada Italy 19 492 0.6× 431 0.8× 225 0.5× 222 1.3× 57 0.4× 45 883
Fernando O. Recio United States 19 416 0.5× 350 0.7× 371 0.9× 181 1.1× 84 0.7× 45 994

Countries citing papers authored by Garry V. Krepart

Since Specialization
Citations

This map shows the geographic impact of Garry V. Krepart's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Garry V. Krepart with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Garry V. Krepart more than expected).

Fields of papers citing papers by Garry V. Krepart

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Garry V. Krepart. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Garry V. Krepart. The network helps show where Garry V. Krepart may publish in the future.

Co-authorship network of co-authors of Garry V. Krepart

This figure shows the co-authorship network connecting the top 25 collaborators of Garry V. Krepart. A scholar is included among the top collaborators of Garry V. Krepart based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Garry V. Krepart. Garry V. Krepart is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lotocki, Robert, et al.. (2008). Cervical Cancer in the Province of Manitoba: A 30-Year Experience. Journal of Obstetrics and Gynaecology Canada. 30(9). 788–795. 1 indexed citations
2.
Lotocki, Robert, et al.. (2005). Stage II endometrial carcinoma: Limiting post-operative radiotherapy to the vaginal vault in node-negative tumors. Gynecologic Oncology. 98(3). 434–438. 22 indexed citations
3.
Faught, Wylam, Tien Le, Michael Fung Kee Fung, et al.. (2003). Early Ovarian Cancer: What Is the Staging Impact of Retroperitoneal Node Sampling?. Journal of Obstetrics and Gynaecology Canada. 25(1). 18–21. 17 indexed citations
4.
Le, Tien, et al.. (2002). The Benefits of Comprehensive Surgical Staging in the Management of Early-Stage Epithelial Ovarian Carcinoma. Gynecologic Oncology. 85(2). 351–355. 88 indexed citations
5.
Nagy, Éva, et al.. (2000). Antiestrogens affect both pathways of killer cell-mediated oncolysis.. PubMed. 20(3A). 1849–53. 7 indexed citations
6.
Le, Tung B. K., Garry V. Krepart, Robert Lotocki, & M. Heywood. (1999). Clinically Apparent Early Stage Invasive Epithelial Ovarian Carcinoma: Should All Be Treated Similarly?. Gynecologic Oncology. 74(2). 252–254. 19 indexed citations
7.
Le, Tung B. K., Garry V. Krepart, Robert Lotocki, & M. Heywood. (1997). Does Debulking Surgery Improve Survival in Biologically Aggressive Ovarian Carcinoma?. Gynecologic Oncology. 67(2). 208–214. 86 indexed citations
8.
Le, Trung, Garry V. Krepart, Robert Lotocki, & M. Heywood. (1997). Malignant Mixed Mesodermal Ovarian Tumor Treatment and Prognosis: A 20-Year Experience. Gynecologic Oncology. 65(2). 237–240. 39 indexed citations
9.
Faught, Wylam, Garry V. Krepart, Robert Lotocki, & M. Heywood. (1994). Should Selective Paraaortic Lymphadenectomy Be Part of Surgical Staging for Endometrial Cancer?. Gynecologic Oncology. 55(1). 51–55. 41 indexed citations
10.
Lotocki, Robert, et al.. (1992). Glassy cell carcinoma of the cervix: A bimodal treatment strategy. Gynecologic Oncology. 44(3). 254–259. 24 indexed citations
11.
Swenerton, K., Gavin Stuart, Moni Roy, et al.. (1992). Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group.. Journal of Clinical Oncology. 10(5). 718–726. 155 indexed citations
12.
Fung, Michael Fung Kee, et al.. (1991). Tubular Krukenberg tumor in pregnancy with virilization. Gynecologic Oncology. 41(1). 81–84. 16 indexed citations
13.
Monga, Manju, John A. Carmichael, Wendy Shelley, et al.. (1991). Surgery without adjuvant chemotherapy for early epithelial ovarian carcinoma after comprehensive surgical staging. Gynecologic Oncology. 43(3). 195–197. 39 indexed citations
14.
Krepart, Garry V., et al.. (1991). Carcinoma of female urethra. Urology. 37(2). 106–109. 21 indexed citations
15.
Ghatage, Prafull, Garry V. Krepart, & Robert Lotocki. (1990). Factor analysis of false-negative second-look laparotomy. Gynecologic Oncology. 36(2). 172–175. 12 indexed citations
16.
Shelley, Wendy, Robert Fraser, Mary Ellen Kirk, et al.. (1988). Adriamycin and cisplatin in the treatment of stage III and IV epithelial ovarian carcinoma. Gynecologic Oncology. 29(2). 208–221. 17 indexed citations
17.
OʼConnell, G., Wendy Shelley, J. Carmichael, et al.. (1987). High-dose-intensity regimen of weekly doxorubicin and cisplatin in the treatment of patients with stage III and IV epithelial ovarian carcinoma.. PubMed. 71(5). 455–8. 3 indexed citations
18.
Jeffrey, J.F., Garry V. Krepart, & Robert Lotocki. (1986). Papillary Serous Adenocarcinoma of the Endometrium. Obstetrics and Gynecology. 67(5). 670–674. 76 indexed citations
19.
Nation, Jill & Garry V. Krepart. (1986). Ovarian carcinoma of low malignant potential: Staging and treatment. American Journal of Obstetrics and Gynecology. 154(2). 290–293. 54 indexed citations
20.
Krepart, Garry V., et al.. (1984). Results of prior cytologic screening in patients with a diagnosis of Stage I carcinoma of the cervix. American Journal of Obstetrics and Gynecology. 148(5). 690–694. 41 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ernst Simonsen Breakdown of academic impact, for papers by A.C.M. van Lindert Breakdown of academic impact, for papers by G Bratina Breakdown of academic impact, for papers by Jackson B. Beecham Breakdown of academic impact, for papers by R E Scully Breakdown of academic impact, for papers by Jan C. Seski Breakdown of academic impact, for papers by Charles Whitney Breakdown of academic impact, for papers by Larry E. Puls Breakdown of academic impact, for papers by Mario Valenzano Menada Breakdown of academic impact, for papers by Fernando O. Recio
Rankless by CCL
2026